{"changed_paths":["/protocolSection/identificationModule/orgStudyIdInfo/id","/protocolSection/statusModule/statusVerifiedDate","/protocolSection/statusModule/overallStatus","/protocolSection/statusModule/completionDateStruct/date","/protocolSection/statusModule/completionDateStruct/type","/protocolSection/statusModule/lastUpdateSubmitDate","/protocolSection/statusModule/lastUpdatePostDateStruct/date","/protocolSection/statusModule/whyStopped","/protocolSection/statusModule/resultsFirstSubmitDate","/protocolSection/statusModule/resultsFirstSubmitQcDate","/protocolSection/statusModule/resultsFirstPostDateStruct","/protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorFullName","/protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorTitle","/protocolSection/outcomesModule/primaryOutcomes/0/measure","/protocolSection/outcomesModule/primaryOutcomes/0/timeFrame","/protocolSection/outcomesModule/primaryOutcomes/0/description","/protocolSection/outcomesModule/primaryOutcomes/1","/protocolSection/outcomesModule/secondaryOutcomes/0/measure","/protocolSection/outcomesModule/secondaryOutcomes/0/timeFrame","/protocolSection/outcomesModule/secondaryOutcomes/0/description","/annotationSection","/hasResults","/resultsSection","/documentSection"],"citation_text":"TrialDiff Evidence Record evt_NCT01147016_v18_v19_b05049cb557e. ClinicalTrials.gov NCT01147016, versions 18-19. Evidence version 1.","claims_not_supported":["That the amendment was scientifically unjustified.","That the change constitutes misconduct or wrongdoing.","That sponsor intent can be inferred from this registry change.","That the change caused or altered the trial's results.","That the change was or was not disclosed in a manuscript.","That TrialDiff determines regulatory compliance or non-compliance.","That TrialDiff determines whether the stopped-trial explanation satisfies 42 CFR 11.64.","That co-occurrence with results posting proves the outcome edit was harmless, administrative, or substantively benign.","That event-class membership is a validated global review-priority ranking."],"claims_supported":["TrialDiff compared ClinicalTrials.gov record version 18 to version 19 for NCT01147016.","The JSON Patch for this comparison has hash 0b069cf9f3969fbcd776537be319c59270cbde482972a162c52805709b9bed98.","The active deterministic rule set hash was fc87f4f0a74bc789dbe4ba85893c2c96f55db62c22970be4e991288104291621.","The deterministic triage label was high; before timing adjustment it was high.","The triage label is uncalibrated metadata, not a validated review-priority finding.","The patch satisfied these deterministic event-class predicates: outcome_edit_cooccurs_with_results_posting.","A registry field under the status or stopped-trial explanation module changed between ClinicalTrials.gov versions 18 and 19.","The timing context for the from-version record was late_recruitment.","The deterministic rules that fired were: terminal_status_change, why_stopped_change.","The changed JSON Pointer paths were: /protocolSection/identificationModule/orgStudyIdInfo/id, /protocolSection/statusModule/statusVerifiedDate, /protocolSection/statusModule/overallStatus, /protocolSection/statusModule/completionDateStruct/date, /protocolSection/statusModule/completionDateStruct/type, /protocolSection/statusModule/lastUpdateSubmitDate, /protocolSection/statusModule/lastUpdatePostDateStruct/date, /protocolSection/statusModule/whyStopped, /protocolSection/statusModule/resultsFirstSubmitDate, /protocolSection/statusModule/resultsFirstSubmitQcDate, /protocolSection/statusModule/resultsFirstPostDateStruct, /protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorFullName, /protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorTitle, /protocolSection/outcomesModule/primaryOutcomes/0/measure, /protocolSection/outcomesModule/primaryOutcomes/0/timeFrame, /protocolSection/outcomesModule/primaryOutcomes/0/description, /protocolSection/outcomesModule/primaryOutcomes/1, /protocolSection/outcomesModule/secondaryOutcomes/0/measure, /protocolSection/outcomesModule/secondaryOutcomes/0/timeFrame, /protocolSection/outcomesModule/secondaryOutcomes/0/description, /annotationSection, /hasResults, /resultsSection, /documentSection.","The timeline value moved by 493 days.","An outcome path changed between versions 18 and 19 in a patch that also carried a hasResults or resultsSection co-occurrence signal.","The changed paths include the ClinicalTrials.gov whyStopped field, a stopped-trial explanation field relevant to 42 CFR 11.64 when applicable."],"classification":{"calibration_status":"uncalibrated","categories":["status_termination","timeline_actualized_earlier","results_reconciliation"],"category":"status_termination","deterministic_rules":["terminal_status_change","why_stopped_change"],"event_class_rule_set_hash":"74a6f55a686c29aa023171acd6b43f27ea95f2b0af2d49094ac70287ba4e502c","event_classes":["outcome_edit_cooccurs_with_results_posting"],"rule_set_hash":"fc87f4f0a74bc789dbe4ba85893c2c96f55db62c22970be4e991288104291621","severity":"high","severity_pre_timing":"high","timing_context":"late_recruitment","triage_label":"high","triage_rule_set_hash":"af5e5835e00a5fcfe2a17fd02b5fc244c2564104f93f78a1d77d7889f12a178b","value_signals":[{"category":"timeline_actualized_earlier","date_struct":"completionDateStruct","delta_days":493,"direction":"earlier","new_precision":"day","new_type":"ACTUAL","new_value":"2017-07-26","old_precision":"month","old_type":"ESTIMATED","old_value":"2018-12","path":"/protocolSection/statusModule/completionDateStruct/date","severity":"low","signal":"timeline_actualized_earlier"},{"category":"results_reconciliation","paths":["/protocolSection/outcomesModule/primaryOutcomes/0/description","/protocolSection/outcomesModule/primaryOutcomes/0/measure","/protocolSection/outcomesModule/primaryOutcomes/0/timeFrame","/protocolSection/outcomesModule/primaryOutcomes/1","/protocolSection/outcomesModule/secondaryOutcomes/0/description","/protocolSection/outcomesModule/secondaryOutcomes/0/measure","/protocolSection/outcomesModule/secondaryOutcomes/0/timeFrame"],"severity":"low","signal":"results_reconciliation_outcome_suppression"}]},"event_id":"evt_NCT01147016_v18_v19_b05049cb557e","evidence_version":1,"patch":[{"op":"replace","path":"/protocolSection/identificationModule/orgStudyIdInfo/id","value":"2010-056(b)"},{"op":"replace","path":"/protocolSection/statusModule/statusVerifiedDate","value":"2023-04"},{"op":"replace","path":"/protocolSection/statusModule/overallStatus","value":"TERMINATED"},{"op":"replace","path":"/protocolSection/statusModule/completionDateStruct/date","value":"2017-07-26"},{"op":"replace","path":"/protocolSection/statusModule/completionDateStruct/type","value":"ACTUAL"},{"op":"replace","path":"/protocolSection/statusModule/lastUpdateSubmitDate","value":"2023-04-05"},{"op":"replace","path":"/protocolSection/statusModule/lastUpdatePostDateStruct/date","value":"2023-04-27"},{"op":"add","path":"/protocolSection/statusModule/whyStopped","value":"Primary co-investigator leaving the institution & funding transfer."},{"op":"add","path":"/protocolSection/statusModule/resultsFirstSubmitDate","value":"2020-12-21"},{"op":"add","path":"/protocolSection/statusModule/resultsFirstSubmitQcDate","value":"2023-04-05"},{"op":"add","path":"/protocolSection/statusModule/resultsFirstPostDateStruct","value":{"date":"2023-04-27","type":"ACTUAL"}},{"op":"replace","path":"/protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorFullName","value":"Abhinav Deol"},{"op":"replace","path":"/protocolSection/sponsorCollaboratorsModule/responsibleParty/investigatorTitle","value":"Investigator"},{"op":"replace","path":"/protocolSection/outcomesModule/primaryOutcomes/0/measure","value":"Progression-free Survival"},{"op":"replace","path":"/protocolSection/outcomesModule/primaryOutcomes/0/timeFrame","value":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 years.."},{"op":"add","path":"/protocolSection/outcomesModule/primaryOutcomes/0/description","value":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesion"},{"op":"remove","path":"/protocolSection/outcomesModule/primaryOutcomes/1"},{"op":"replace","path":"/protocolSection/outcomesModule/secondaryOutcomes/0/measure","value":"Overall Deaths"},{"op":"replace","path":"/protocolSection/outcomesModule/secondaryOutcomes/0/timeFrame","value":"From date of randomization until date of death from any cause or end of study, whichever came first, assessed up to 7 years"},{"op":"add","path":"/protocolSection/outcomesModule/secondaryOutcomes/0/description","value":"Total number of deaths"},{"op":"remove","path":"/annotationSection"},{"op":"replace","path":"/hasResults","value":true},{"op":"add","path":"/resultsSection","value":{"adverseEventsModule":{"eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":8,"description":"All 8 participants enrolled","id":"EG000","otherNumAffected":8,"otherNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"title":"Treated"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 2","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Hypertension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 1 1 grade 2 5 grade 31","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":8,"numEvents":7}],"term":"chills/rigors"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 5 Grade 2 1","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":8,"numEvents":7}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 3 Grade 2 1","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":8,"numEvents":4}],"term":"Vomiting"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 4 Grade 2 3","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":8,"numEvents":7}],"term":"fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 3","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":8,"numEvents":3}],"term":"Rash"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1 Grade 2 1","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8,"numEvents":2}],"term":"edema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1 Grade 2 1 Grade 3 1","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":8,"numEvents":3}],"term":"neuroppathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 2 5","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":8,"numEvents":5}],"term":"hypotension"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 1 4 Grade 2 2","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":8,"numEvents":6}],"term":"fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"hyponatremia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 2","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8,"numEvents":2}],"term":"hypoglycemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1 Grade 2 1 Grade 3 1 Grade 4 1","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":8,"numEvents":4}],"term":"neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"grade 1 1","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"AST elevation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"ALT elevation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 4 Grade 2 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":8,"numEvents":5}],"term":"Anemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 2 1","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Afibrillation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 2 Grade 2 1","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":8,"numEvents":3}],"term":"Infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 3 Grade 2 2","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":8,"numEvents":5}],"term":"Low platelets"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1 Grade 2 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8,"numEvents":2}],"term":"hypoalbuminemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1 Grade 2 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8,"numEvents":2}],"term":"Alkaline Phosphatase"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 2 Grade 2 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":8,"numEvents":2}],"term":"Hypercalcemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 3 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Hypocalcemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Grade 1 1","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"hypokalemia"}],"timeFrame":"Up to 7 years."},"baselineCharacteristicsModule":{"denoms":[{"counts":[{"groupId":"BG000","value":"8"}],"units":"Participants"}],"groups":[{"description":"Single group study","id":"BG000","title":"Treated"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"39","upperLimit":"52","value":"44.5"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"enrollment","unitOfMeasure":"Participants"}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"email":"aweise3@hfhs.org","organization":"Barbara Ann Karmanos Cancer Institute","phone":"248-344-6688","title":"Dr. Amy Weise"}},"outcomeMeasuresModule":{"outcomeMeasures":[{"classes":[{"categories":[{"measurements":[{"comment":"The sample size is very small and there are too few events to estimate the upper 95% CI.","groupId":"OG000","lowerLimit":"2","upperLimit":"NA","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesion","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants enrolled","id":"OG000","title":"Activated T Cells"}],"paramType":"MEDIAN","populationDescription":"Women with stage II-III, HER2/neu (0-2+) negative breast cancer treated with anti-CD3 x anti-HER2neu (Her2BI) armed, activated T cells after neoadjuvant chemotherapy","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 years..","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Total number of deaths","groups":[{"description":"Single group study","id":"OG000","title":"Treated"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The participant who died had the longest follow-up time.","reportingStatus":"POSTED","timeFrame":"From date of randomization until date of death from any cause or end of study, whichever came first, assessed up to 7 years","title":"Overall Deaths","type":"SECONDARY","unitOfMeasure":"Participants"}]},"participantFlowModule":{"groups":[{"description":"Single group study","id":"FG000","title":"Treated"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}}},{"op":"add","path":"/documentSection","value":{"largeDocumentModule":{"largeDocs":[{"date":"2015-05-12","filename":"Prot_SAP_000.pdf","hasIcf":false,"hasProtocol":true,"hasSap":true,"label":"Study Protocol and Statistical Analysis Plan","size":1679294,"typeAbbrev":"Prot_SAP","uploadDate":"2020-09-30T15:45"}]}}}],"provenance":{"from_snapshot_hash":"b0137277adcbac77968ab195a485563d983c6ae71845fadc728bcd189ddef176","materiality_event_hash":"a5e632a8477cfaaa3456d4c5a0df212e9a5287412fb0bf8c6f9ff856ff6b631c","patch_hash":"0b069cf9f3969fbcd776537be319c59270cbde482972a162c52805709b9bed98","patch_raw_hash":"9b6c7f6485e8daa25afd47cbe36cf6f7981086283bb15fcc03b5f00942dd3f66","patch_source":"ctgov_internal_history","patch_source_url":"https://clinicaltrials.gov/api/int/studies/NCT01147016/history/18?patchToVersion=19","to_snapshot_hash":null},"review_question":"Does the public registry record give a specific explanation for the stopped or terminal status?","schema":"trialdiff.evidence_record","trial":{"clinicaltrials_gov_url":"https://clinicaltrials.gov/study/NCT01147016","nct_id":"NCT01147016"},"versions":{"from_version":18,"submitted_date":"2023-04-05","to_version":19}}